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ABSTRACT—Our objective was to investigate the significance of endogenous endothelin-1 -induced sys-
temic circulatory reactions during hypodynamic sepsis. In the first part of this study, we observed the 
changes in global hemodynamic parameters in Wistar rats after exogenous endothelin-1 administration in 
order to test an intervention strategy aimed at preventing the development of hypodynamic cardiovascular 
derangement during intraabdominal sepsis. Cardiac output, mean arterial blood pressure, and peripheral 
vascular resistance were recorded, and the-endotheiin-A receptor antagonist BQ-610 and the endothelin-B 
receptor antagonist IRL-1038 were used to investigate the role of receptor subtypes in circulatory changes. 
In addition, the effects of treatment with the novel endothelin-A receptor inhibitor ETR-P1/A peptide were 
examined in endothelin-1-treated anesthetized rats. The injection of 1 nmol/kg endothelin-1 induced a 
significant rise in peripheral vascular resistance, a transient increase in mean arterial pressure, and a 
decrease in cardiac output. Administration of the endothelin-A receptor antagonist BQ-610 and ETR-P1/ÍI 
peptide increased cardiac output and decreased systemic vascular resistance in the controls and in 
animals treated with exogenous endothelin. In the second part of the study, the animals were instrumented 
for hemodynamic monitoring and randomized to undergo cecal ligation and perforation for 8 h or control 
laparotomy. Septic animals with cecal ligation and puncture were normotensive and hypodynamic, with a 
significantly increased total peripheral resistance throughout the 8 h observation period. ETR-P1/fl peptide 
treatment started after the induction of sepsis significantly increased cardiac output and decreased 
systemic vascular resistance almost to control levels. We conclude that endogenous endothelin-1 contrib-
utes significantly to the systemic hemodynamic alterations during hypodynamic circulatory response, and 
the inhibition of endothelin-A receptors may improve global hemodynamic status in this phase of sepsis. 
INTRODUCTION 
It is now recognized that endothelial cell-derived vasocon-
strictor and vasodilator mediators play an important role in 
vascular control in pathologic processes and cause critical 
changes in systemic vascular resistance, blood pressure, and 
distribution of flow. The endothelins (ETs) are a family of 
powerful endogenous vasoconstrictor peptides produced by 
endothelial cells (1,2) . Three active isoforms (ET-1, ET-2, and 
ET-3) and two main receptor types (ETA and ETU) for ETs 
have been recognized and cloned to date (3-6) . The receptors 
mediate different circulatory effects depending on their local-
ization, but it is suggested that vasoconstriction is mediated 
predominantly via the ETA receptors, while the activation of 
ET0 receptors elicits both vasodilator and vasoconstrictor re-
sponses in mammals (7-10). 
Recent studies have demonstrated that the production of 
ET-i rises rapidly during experimental and clinical endotox-
emia and sepsis, which suggests that ET-1 may contribute to 
the regulation of vascular tone under these conditions (11-14). 
Sepsis and septic shock are the most common causes of death 
in the surgical intensive care unit. Although the acquisition of 
information about the role of ET-1 could have therapeutic 
consequences, the currently available experimental results are 
incompletely understood. Because of the continual transitions 
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between hyper- and hypodynamic circulatory responses, it is 
difficult to compare data obtained in various progressive stages 
of sepsis. In addition, the question as to whether increased 
plasma levels of ET-1 are primary or secondary phenomena is 
still controversial. 
Our main objective was to investigate the role of endoge-
nous ET-1 in the systemic circulalory changes occurring during 
hypodynamic sepsis in anesthetized rats. In an attempt to gain 
further insight into this process, the characteristics of exoge-
nous ET-l-induced systemic circulatory reactions with or with-
out ET receptor antagonist pretreatment were investigated in 
order to establish a pattern for comparison with the circulatory 
consequences of intraabdominal sepsis. We determined the 
systemic hemodynamic effects of exogenous ET-1, which 
causes circulatory changes that are similar to those observed 
during hypodynamic sepsis. The involvement of ETA and ETB 
receptors was assessed by using the selective receptor antago-
nists BQ-610 and IRL-1038, respectively. 
In the second part of our study, circulatory reactions were 
recorded in rats randomized to undergo cecal ligation and 
perforation (CLP) or control laparotomy. The increase in the 
RNA message of the ET precursor is apparent 6 h after an 
endotoxin challenge (14), and we therefore observed global 
hemodynamics for 8 h following the induction of intraabdomi-
nal sepsis by CLP. In addition, the effects of treatment with the 
novel ETA receptor antagonist, ETR-Pl/fl peptide, were inves-
tigated. ETR-Pl/f l is a recently designed "antisense-homology 
box"-derived peptide,-which exhibits potent anti-ETA receptor 
• • 
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activity in vitro (15). Here, we present the first data on the 
effects of the ET receptor antagonist ETR-Pl/fl peptide on the 
septic systemic vascular changes in the rat. Our results dem-
onstrate that ET-1 is an instrumental component of the circu-
latory alterations during the hypodynamic phase of sepsis, and 
that these changes can be influenced significantly by an ETA 
receptor-targeted treatment regimen. 
MATERIALS AND METHODS 
The experiments were performed in adherence to the National Institutes of 
Health guidelines for the use of experimental animals. The study was approved 
by the Ethical Commit tee for the Protection of Animals in Scientific Research 
of Szem-GytSrgyi Albert Medical University. 
Surgical procedure 
38 male Wistar rats (weighing 250 i 15 g) were deprived of food, but not 
water, for 12 h prior to the experiments. The animals were anesthetized with 
sodium pentobarbital (60 mg/kg body weight intraperi toneal lyrand placed in 
a supine position on a heating pad. and tracheotomy was performed. The right 
jugular vein was cannulated with PE50 tubing for fluid administration. The left 
common carotid artery was exposed, and a thermistor-tip catheter was ad-
vanced into the ascending aorta to measure cardiac output (CO) by a ther-
modilution technique. The right femoral artery was cannulated for mean 
arterial pressure (MAP) and heart rate (HR) measurements . CO. HR. and M A P 
values were recorded, and the total peripheral resistance (TPR) was calculated 
by means of a Cardiostar CO-100 computer (Experimetria Ltd., Budapest, 
Hungary). Following a midline laparotomy, the animals were divided into two 
experimental series. 
Experimental protocol 
T w o series of experiments (with nonseptic controls and septic animals) 
were performed to investigate the ef fec ts of ET A receptor antagonism in 
hypodynamia sepsis. Alt animals received a continuous infusion of isotonic 
saline at a rate of 3 ML/H/kg. Af ter surgery, the animals were allowed to 
stabilize for 30 mm, and the cardiovascular parameters were then recorded to 
establish the baseline variables. The ET A and ET„ receptor antagonists alone 
were given intravenously (i.v.) to normal rats In pilot studies. 
In the first series of experiments, ET-I was administered alone or in 
combination with the ET receptor antagonists, in group 1 (n = 6), a solution 
of 1 nmoi/kg ET-1 (Alexis Corp., Laufel f tngen, Switzerland) was infused i.v. 
into the systemic circulation with a syringe pump, and the hemodynamic 
parameters were then observed for a further 70 mitt. 
In groups 2 - 5 (n = 6 in each group), the ET A receptor antagonist BQ-610 
(homopiperidinyl-carbonyl-Leu-D-Trp(CHO)-D-Trp-OH (16). Alexis Corp., 
Laufelftngen, Switzerland, 100 nmol/kg (17)). ETR-P l / f ! peptide (VLNL-
CALS V D R Y R A V A S W R V I , Kurabo Ltd., Osaka, Japan. 100 nmol/kg), or the 
E T b receptor blocker IRL-1038 (Cyst 1 -Cys t5 -ET- l (11-21) , Alexis Corp. . 
100 nmol/kg (18. 19)) was infused i.v. into the systemic circulation over 10 
min. In these groups, 10 min after the end of IRL-1038, BQ-610, or ETR-P l / f l 
peptide pretreatment, ET-1 in a 1. nmol/kg dose was Infused i.v. over 10 min, 
and the circulatory effects were observed for another 70 min. 
In the second set of experiments, the animals were instrumented as above 
and were randomized af ter laparotomy. 
In group 6 (n = 6), the base of the cecum was exteriorized, ligated, and 
punctured six times (CLP) with a 20-gauge needle. Upon completion of the 
surgical procedure, (he abdomen was closed and the cardiovascular parameters 
were registered during a further 8 h period, in pilot studies, we established that 
this injury results in reproducible circulatory changes throughout the experi-
ments. 
In group 7 (n = 6), 100 nmol/kg ETR-Pl / f l peptide was infused i.v. 10 min 
after CLP. 
In group 8 (n = 6), a sham operation was performed, and the abdomen was 
closed without CLP. 
During the experimental period, MAP, HR, CO, and TPR were measured 
every 30 min. 
Statistical analysis 
Data analysis was performed with a statistical software package (SigmaStat 
for Windows. Jandel Scientific, Erkrath, Germany). Nonpamtnetric methods 
were used. Friedman repeated measures analysis of variance on ranks was 
applied within groups. Time-dependent differences f rom the baseline were 
analyzed by Dunn ' s method. Differences between groups were analyzed with 
the Mann-Whi tney rank-sum test (between two groups) and Kruskal-Wallis 
one-way analysis of variance on ranks (among groups), /J values < .05 were 
considered significant. 
RESULTS 
The resting hemodynamic parameters were similar in each 
of the groups studied. Administration of the ETA receptor 
antagonist ETR-Pl/f l peptide and BQ-610 induced a transient, 
approximately 10% decrease in MAP and a 10% increase in 
CO, while the HR values did not change significantly. The ETB 
receptor antagonist IRL-1038 did not exert any significant 
effect on these parameters. 
Infusion of I nmol/kg ET-1 induced an immediate signifi-
cant rise by 250% in TPR (Fig. I). After 30 min, MAP had 
time (min) 
time (min) 
FIG. 1. Changes in the TPR (upperpanel) and CO (lowerpanel) in 
rats treated with 1 nmol/kg ET-1 (O) and in animals that received an 
ET receptor antagonist pretreatment. • : IRL-1038 + ET-1 pretreat-
ment (n = 5); • : ETR-P1/fl peptide + ET-1 pretreatment (n = 5); • : 
BQ-610 + ET-1 pretreatment (n = 5). Values are means ± standard 
error. *p < .05 vs. ET-1-treated group; "p < .05 vs. baseline value 
(Kruskal-Wallis one-way analysis of variance on ranks and Friedman 
test). 
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TABLE 1. Hemodynamic data: Effects of ET-A and ET-B receptor antagonists on exogenous ET-1-induced circulatory responses 
Treatment 
ET receptor Measurement CO TPR MAP 
ET-1 antagonist times n (mL/min/kg) (mmHg/mL-min-kg) (mmHg) 
+ - Baseline 6 258 ± 11.1 0.51 ± .02 131 £ 3.8 
+ - 15 min 6 113 ± 7.3* 1.36 £ .09* 153 £ 8 
+ - 30 min 6 183 ± 15.3* .90 ± .07* 163 £ 8.3* 
+ - 70 min 6 206 £ 16.8 .71 £ .05 143 £ 7.5 
+ ETR-P1/Í1 Baseline 5 264 ± 8.6 .46 ± .01 122 £ 6.1 
+ ETR-Pl/fl 15 min 5 177 i 8.5** .74 ± .02* 130 £ 3.2 
+ ETR-P1/Í1 30 min 5 223 £ 10.6 .62 £ .02* 136 £ 2.1* 
+ ETR-P1/f1 70 min 5 256 £ 6.8* .46 £ .02* 118 £6.7 
+ BQ 610 Baseline 5 258 ± 5.5 .50 £ .02 127 £ 3.3 
+ BQ 610 15 min 5 238 £ 9.3* .58 £ .02* 138 £ 7.2 
+ BQ 610 30 min 5 243 £ 6* .52 £ .03* 126 £ 4.4* 
+ BQ 610 70 min 5 249 ± 9.8 .53 £ .02 131 £ 4.3 
+ IRL 1038 Baseline 5 274 £ 12 .50 £ .02 137 £ 1.6 
+ IRL 1038 15 min 5 156 £ 16* 1.06 £ .15* 155 £ 4.2 
+ IRL 1038 30 min 5 203 ± 8.7* .77 £ .04* 153 £ 6 
+ IRL 1038 70 min 5 227 ± 10.1 .55 £ .04 123 £ 6.8 
Values are expressed as means ± standard error. 
*p < .05 versus baseline value. 
*p < .05 versus ET-1 treated group. 
increased from 131 to 163 mmHg (Table 1). This hypertension 
was associated with a significant decrease in CO from 258 
mL/min/kg (baseline value) to 183 mL/min/kg. 
Pretreatment with ETR-Pl/fl peptide and BQ-610 signifi-
cantly attenuated the ET-1-induced increase in MAP and re-
duced the decrease in CO. Similarly, at 40 min, 1RL-1038 
effectively diminished the elevation in MAP, but this pretreat-
ment did not influence the ET-1-induced fall in CO (Tabie 1). 
The increase induced in TPR by ET-1 was reduced by BQ-610 
and ETR-Pl/fl pretreatment, whereas IRL-1038 was ineffec-
tive (Fig. 1). 
CLP induced a significant fall in CO after 90 min (from 
283 ± 25 mL/min/kg to 246 ± 24 mL/min/kg), which devel-
oped progressively over the following 3 h and remained de-
pressed until the end of the 8 h observation period (Fig. 2). 
TPR displayed early increases, with a maximum at 3 h, and 
remained elevated throughout the experiments. In these ani-
mals, there was a small reduction in MAP after 8 h, but this 
was not statistically significant as compared with the baseline 
or the sham-operated values (Table 2). 
Administration of ETR-Pl/fl peptide after CLP delayed and 
inhibited the reduction in CO, so that there was no significant 
CO decrease during the 8 h observation (Fig. 2). Additionally, 
ETR-Pl/fl peptide treatment significantly reduced the CLP-
induced increase in TPR during the experiments. The change in 
MAP did not differ from the corresponding value for the 
sham-operated or CLP-treated group throughout the observa-
tion period (Table 2). 
DISCUSSION 
The time course of septic metabolic, humoral, and hemody-
namic responses is classically resolved into two parts (20). The 
hyperdynamic state is characterized by an early decrease in 
systemic resistance and mean blood pressure and an increase in 
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FIG. 2. Changes in TPR (upper panel) and CO (lower panel) in 
sham-operated controls (O, n = 5), in 8 h CLP-treated animals p , 
n = 5), and in rats that received ETR-P1/fl peptide treatment (•, n = 
5) 10 min after CLP. Values are means £ standard error, 'p < .05 vs. 
control group; "p < .05 vs. baseline value (Kruskal-Wallis one-way 
analysis of variance on ranks and Friedman test). 
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TABLE 2 . Effects of ETR-P1/f1 peptide treatment on hemodynamic changes in rats with cecal ligation and puncture (CLP) 
CLP 
Treatment 
ETR-Pl/fl 
peptide 
Measurement 
times n 
CO 
(mL/min/kg) 
TPR 
(mmHg/mL-min-kg) 
MAP 
(mmHg) 
- - Baseline 6 300 £ 6.2 .46 £ .01 136 £ 4.3 
- - 90 min 6 316 £ 16.2 .43 £ .02 134 £ 3.8 
- - 180 min 6 329 ± 14.2 .40 £ .02 129 £ 4.3 
- - 480 min 6 279 £ 24.6 .48 £ .03 129 £ 4.5 
+ - Baseline 5 283 £ 25.4 .54 £ .03 148 £ 6.1 
+ - 90 min 5 246 £ 24.3* .57 £ .03* 139 £ 10.6 
+ - 180 min 5 224 £ 20.3* .63 £ .04* 140 £ 9.8 
+ - 480 min 5 208 £ 22.1* .58 £ .07 118 £ 12.6 
+ + Baseline 6 ' 303 £ 1 1 .46 £ .03 138 £ 5 
+ + 90 min 6 315 £ 11.1« .44 £ .04« 136 £ 7 
+ + 180 min 6 288 ± 10.4« .42 £ .01« 120 £ 3.6 
+ + 480 min 6 253 £ 19.3 .44 £ .04 109 £ 8.8 
Values expressed as means £ standard error. 
*p < 0.05 vs. sham-operated group. 
Jp < 0.05 vs. baseline value. 
5p < 0.05 between ETR-P1/f1 -treated and untreated CLP groups. 
CO. During the hypodynamic phase, a moderate decrease in 
MAP is accompanied by a substantial fall in CO. The systemic 
vascular resistance increases, leading to a marked reduction in 
the perfusion of the intestine, kidneys, and skin, while the 
blood flow is redistributed to the vital organs (21). The results 
of the present study show that ET-1 causes hemodynamic 
changes similar to those observed during hypodynamic sepsis, 
and that some of these effects can be influenced significantly 
by treatment with an ET receptor antagonist. 
First, we compared the abilities of ET-1 and ET receptor 
antagonists to influence the systemic hemodynamics in normal 
rats. The ETB receptor antagonist IRL-1038 alone had no direct 
effects on any of the systemic parameters measured, but the 
E T a receptor antagonist BQ-610 and ETR-PI/fl peptide in-
duced a transient fall in MAP, implicating a role for ET-1 in 
the maintenance of vascular tone. This is in agreement with the 
findings of Haynes et al. (22) in humans, but it may contrast 
with what is found in other studies in normotensive rats (23, 
24). A possible explanation is that BQ-610 is 30 limes more 
potent than BQ-123, a widely used ETA receptor antagonist 
(16). Additionally, we used the novel antisense-homology box-
derived ET receptor antagonist ETR-PL/fl peptide, which binds 
to distinct regions of the ETA receptor (15). Briefly, ETR-Pl/fl 
peptide is an amphiphilic peptide fragment of the human ETA 
receptor responsible for the maintenance of protein shape. It 
has been demonstrated that the peptide significantly reduces 
the constrictor effect of ET-1 in isolated vessels and actively 
inhibits the ET-l-induced Ca 2 + influx in vitro (15). 
There is good evidence that plasma levels of ET-1 are 
significantly elevated in experimental animals and in humans 
with sepsis and endotoxemia (11-14). In our study, we admin-
istered ET-1 to establish a pattern for comparison with the 
sequence of CLP-induced circulatory changes. The increase in 
MAP after ET-1 was accompanied by a rise in TPR, despite a 
fall in CO. The decrease in CO was most probably due to a 
reduction in stroke volume. These effects of ET-1 are possibly 
mediated by ETA receptors present in the circulation, as ad-
ministration of the specific ETA receptor antagonist BQ-610 
and ETR-Pl/fl peptide significantly inhibited both the ET-l-
induced increases in TPR and MAP and the decrease in CO. 
However, it should be noted that selective blockade of the ETB 
receptors with IRL-1038 was partially effective in reducing the 
ET-l-induced changes. This suggests that the residual re-
sponses to ET-1 in the presence of ETR-Pl/fl peptide may be 
mediated by unblocked ETB receptors, and consequently that 
ETR-Pl/fl peptide is a nonselective inhibitor of ET receptors, 
i.e.. it has dual ETA and ET„ receptor antagonist properties. 
This explanation seems plausible, as the ETR-Pl/fl peptide 
exhibits a close amino acid sequence similarity to an antisense-
homology box present in the ETB receptor (L. Baranyi, unpub-
lished observation). It may be assumed that the proficiency of 
ET-1 receptor antagonist compounds in inhibiting ET-1-in-
duced central hemodynamic effects is related to their capacity 
to antagonize an activation of vasoconstriction-mediating ET 
receptors on vascular smooth muscle cells (e.g., ETA and ETB2 
receptors). 
The hemodynamic changes of sepsis and endotoxemia in-
volve several vasodilator and vasoconstrictor factors, but the 
activated endothelium clearly participates in and regulates the 
process (25). This is achieved by the production of a variety of 
vasoactive mediators, including ET-1. ET-1 release is stimu-
lated in vitro by tumor necrosis factor a and endotoxin (26, 
27). The tissue expression of ET-1 mRNA is significantly 
increased 6 h after the in vivo injection of endotoxin, and the 
ET-1 level reaches its maximum 8 h after CLP in rats (14,28). 
We aimed to investigate sepsis-induced circulatory changes 
in an acute model that mimics human sepsis more closely than 
endotoxin infusion. The 8 h CLP resulted in a septic hemody-
namic state similar to that observed in patients during hypo-
dynamic sepsis. A transient, initial hyperdynamic response was 
followed by a simultaneous increase in systemic resistance and 
a decrease in CO. The MAP remained stable. 
Our main objective was to determine whether ET-1 partic-
ipates in the circulatory alterations during hypodynamic sepsis, 
and the systemic hemodynamic changes that we recorded fol-
lowing 8 h of intraabdominal sepsis, with or without ET 
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receptor antagonist treatment, are in agreement with this hy-
pothesis. Peripheral vascular resistance was significantly de-
creased after ETR-Pl/f! peptide administration, suggesting a 
role for ET-I in the hypodynamic circulatory reaction with 
respect to central tension regulation. However, it is still unclear 
whether ET-I is a compensatory or detrimental factor of the 
septic hemodynamic derangement, because at least two possi-
bilities should be considered. First, it should be noted that, 
among many other modes of action, ET-l decreases CO and 
increases peripheral vascular resistance, and hence, tissue dam-
age may be due to the maintenance of impaired peripheral 
tissue perfusion. This ongoing process can be blocked by the 
ET a receptor antagonist ETR-Pl/fl peptide. On the other hand, 
the ET-I-induced increase in peripheral resistance may be an 
important compensatory factor in maintaining circulatory sup-
port, so that antagonism of the vasoconstrictor ET receptors 
might be detrimental in the long run (29, 30). 
In our severe hypodynamic sepsis model, the decrease in CO 
was significantly attenuated by ETR-Pl/fl peptide administra-
tion. Similarly, the changes in TPR demonstrated that inhibi-
tion of the ETA receptors did not impair the global hemody-
namic status in this phase of sepsis in the rat. Thus, it seems 
that the increased circulating ET-1 output under hypodynamic 
septic conditions is involved in global hemodynamic derange-
ments via ETA receptor activation. An ETA predominance is 
most likely in the rat circulation, and the ETA receptors and (to 
a lesser extent) the ETB receptors mediate vasoconstriction and 
may ultimately contribute to a reduced peripheral organ per-
fusion in hypodynamic septic states. As ET-1 has a higher 
affinity for ETA than for ETn receptor subtypes, these results 
demonstrate that the ETA receptor is more important in the 
production of these changes (31, 32). These data, and the 
observations of elevated plasma levels during sepsis and en-
dotoxemia, suggest a therapeutic potential for ETA receptor 
antagonists in these conditions. 
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DYNAMIC IN VIVO OBSERVATION OF VILLUS 
MICROCIRCULATION DURING SMALL BOWEL 
AUTOTRANSPLANTATION: EFFECTS OF ENDOTHELIN-A 
RECEPTOR INHIBITION1 
ANTAL WOLFÁRD,2,3 LÁSZLÓ SZALAY,2 JÓZSEF KASZAKI,2 GÁBOR SAHIN-TÓTH,2 RÓBERT VANGEL,3 
ÁDÁM BALOGH,3 AND MIHÁLY BOROS2,4 
Institute of Surgical Research and Department of Surgery, University of Szeged, Szent-Györgyi Albert Medical Center, 
H-6720 Szeged, Hungary 
Background. T h e a ims of th is s t udy were to charac te r -
ize the s t r u c t u r a l a n d microc i rcu la to ry changes in single 
intes t inal villi d u r i n g i schemia a n d r epe r fus ion a n d de te r -
mine t h e s i te of ac t ion of endo the l in (ET)-A recep to r inhi-
bi t ion d u r i n g compromised mucosa l per fus ion . 
Methods. Small bowel a u t o t r a n s p l a n t a t i o n w a s per-
fo rmed in anes the t i zed dogs. O n e g r o u p w a s t r ea t ed wi th 
the ET-A r ecep to r an t agon i s t ETR-pl/f l pept ide . T h e epi-
thelial th ickness a n d villus microc i rcu la tory p a r a m e t e r s 
w e r e observed by o r thogona l polar iza t ion spec t ra l imag-
ing; t he leukocyte-endothel ia l cell in te rac t ions were quan-
tified wi th fluorescence videomicroscopy. 
Results. S i x t y - m i n u t e co ld i s c h e m i a a n d 240-min 
r e p e r f u s i o n i n d u c e d a d e c r e a s e in v i l l u s f u n c t i o n a l 
c a p i l l a r y d e n s i t y a n d l e u k o c y t e - e n d o t h e l i a l cel l i n t e r -
a c t i o n s . T h e e p i t h e l i a l l a y e r w a s g r a d u a l l y r e m o v e d , 
b u t d e n u d e d vil l i w e r e n o t o b s e r v e d . ET-A r e c e p t o r 
i n h i b i t i o n r e d u c e d t h e l e u k o c y t e a d h e r e n c e a n d a t t e n -
u a t e d e p i t h e l i a l e x f o l i a t i o n a n d t h e d e c r e a s e in v i l lu s 
f u n c t i o n a l c a p i l l a r y d e n s i t y . 
Conclusions. ET-A r e c e p t o r a c t i v a t i o n m e d i a t e s mi-
c r o v a s c u l a r d y s f u n c t i o n t h r o u g h p r e c a p i l l a r y b lock-
a d e s a n d l e u k o c y t e - e n d o t h e l i a l cel l i n t e r a c t i o n s a f t e r 
co ld i s c h e m i a a n d r e p e r f u s i o n in t h e c a n i n e sma l l 
bowe l . 
Although novel immunosuppression strategies have im-
proved the results of small bowel t ransplantat ion (SBTX), 
serious nonimmunological complications limit the success of 
such therapy (I). The impaired capillary perfusion, leuko-
cyte-endothelial cell interactions, and other microvascular 
reactions induced by ischemia-reperfusion usually do not 
cause systemic circulatory manifestat ions but could lead to 
severe t issue injury in the long run (2). In seeking to identify 
novel effective tissue protective agents, a number of authors 
have demonstrated tha t endothelin (ET)-l peptide plays a 
crucial role in ischemia-reperfusion-induced damage of the 
intestinal circulation (3-5). ET-1 is the most powerful vaso-
constrictor substance known to date, and the vasoconstrictive 
effects are mediated predominantly via the endothelin-A 
(ET-A) receptors present on the vascular smooth muscle cells 
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Medical Center. P.O. Box 464, H-6701 Szeged, Hungary 
(6'). We have previously shown tha t the inhibition of ET-A 
receptors improves graft-perfusion, decreases granulocyte 
activation, and extravasation after intestinal ischemia-reper-
fusion (4). In the present experiments, we investigated the 
microvascular al terat ions tha t occur in single intestinal villi 
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FIGURE I. Changes in functional capillary density (cm/cm2) 
(A) and in epithelial thickness (pm) (B) in the SBTX (black 
columns), ETR-pl/fl peptide-treated (gray columns), and 
sham-operated (white columns) groups. The tops of the col-
umns show the median values. The capped bars indicate the 
25th and 75th percentiles, respectively. "PcO.Oo within 
groups vs. baseline values; XP<0.05 between sham-operated 
and SBTX groups; *P<0.05 between SBTX and SBTX+ETR-
pl/fl peptide-treated groups. 
1512 TRANSPLANTATION Vol. 73, No. 9 
FIGURE 2. Micrographie views of the small intestinal mucosa after SBTX. (A) Canine intestinal villi showing typical normal 
microvascular architecture and no significant pathological lesions. Baseline conditions: the epithelium is essentially of 
normal thickness (OPS imaging, original magnification x 100). (B) The epithelial cells at the villus tip are elevated during 
reperfusion. A tapering column is formed, and the exfoliated original epithelial layer is removed. Several capillaries are not 
perfused (1-hr postreperfusion). (C) A new epithelium is closed above the villus stroma; "denuded" villi are not seen. (D) 2-hr 
postreperfusion: short, squat villi and negligible subepithelial lesions. 
in a large-animal model of SBTX devoid of immune effects. 
Secondly, t he microcirculatory effects of selective ET-A re-
ceptor inhibition were characterized. 
Three separa te series of exper iments were performed on a 
total of 15 mongrel dogs under sodium pentobarbital anes-
thesia. The surgical procedure of jejunoileal orthotopic auto-
t ransplanta t ion h a s been described previously (4). After t he 
60-min cold ischemia, reperfusion was induced and the mi-
crohemodynamic changes were observed for 240 min. Trans-
plantat ion was performed in groups 1 (n=5) and 2 (n=5); in 
group 2 the an imals were t rea ted with the ET-A receptor 
antagonist ETR-pl/f l peptide (Kurabo Ltd., Osaka, J a p a n ) in 
a dose of 0.1 mg/kg a t the beginning of revascularization. 
Group 3 (n=5) served as sham-operated control. 
Leukocytes were s tained in vivo with rhodamine-6G (Mw 
479, Sigma, St . Louis, MO, 0.2%, 1 ml i.v.). Leukocyte-endo-
thelial cell interact ions in the postcapillary venules of the 
mesentery were monitored with a high-resolution Zeiss Ax-
iotech Vario 100HD intravi ta l fluorescence videomicroscope 
system. The microscopic images: jp j i sS .Mifazed off-line by 
frame-to-frame analysis of the videotaped images, including 
the observation of adheren t and rolling leukocytes (3). 
Orthogonal polarization spectral (OPS) imaging technique 
(Cytoscan A/R, Cytometrics, PA, USA) was used to monitor 
microvascular perfusion changes in the intest inal villi before 
harves t ing and dur ing the reperfusion phase. This novel 
intravi ta l method utilizes polarized reflected light a t 548 nm 
to visualize hemoglobin-containing s t ructures , without the 
use of fluorescent dyes (7). The objective of the device was 
introduced into the intes t inal lumen, and the functional cap-
illary density (FCD), t he red blood cell velocity (RBCV), the 
d iameter of the central arterioles of the villi, and the thick-
ness of t he epithelial cell layer covering the villi were deter-
mined wi th a computer-assisted image analysis system (Pic-
tron Ltd., Budapest . Hungary) . All da ta were expressed as 
the means of five measu remen t s a t each t ime point. 
Time-dependent differences wi th in groups were analyzed 
with the Fr iedmann and Dunn's method. Differences be-
tween groups were analyzed wi th Kruskal-Wallis one-way 
analysis of var iance on ranks , fol I ciweriJxfeBrnn's method. In 
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FIGURE 3. Percentage of rolling leukocytes (A) and number of 
adherent leukocytes (B) in the mesenteric postcapillary 
venules in the SBTX (black columns), ETR-pl/fl peptide-treated 
(gray columns) and sham-operated (white columns) groups. 
The tops of the columns show the median values. The capped 
bars indicate the 25th and 75th percentiles, respectively. 
XP<0.05 between sham-operated and SBTX groups; *P<0.05 be-
tween SBTX and SBTX+ETR-pl/fl peptide-treated groups. 
the figures, median values and 75th and 25th percentiles are 
given. P va lues<0.05 were considered significant. 
The resul ts show tha t the villus FCD was significantly 
reduced during reperfusion compared with the preharvest ing 
values or with the FCD values of the sham-operated group. 
ET-A receptor inhibition significantly a t tenuated the de-
crease in FCD dur ing the reperfusion phase (Fig. 1A). 
The epithelial thickness remained unchanged in the sham-
operated group, and there was a tendency toward an epithe-
lial height-reduction in both t ransplanted groups. However, 
in the la ter phase the epithelial thickness was significantly 
higher in the ETR-pl/f l peptide-treated group (Fig. IB). 
RBCV decreased slightly, but significantly, during the 
reperfusion phase in both t ransplanted groups in the villus 
arterioles and venules. ETR-pl/fl t r ea tment did not signifi-
cantly influence this parameter . No difference was found 
between the diameters of the villus arterioles and venules 
(data not shown). 
The epithelial cells at the villus tip s tar ted to elevate 
immediately af te r reperfusion. A tapering column was soon 
formed, and the exfoliated original epithelial layer was re-
moved from the sand-glass-like villus. Meanwhile, a new 
epithelial layer was closed above the villus stroma, so that 
"denuded" villi were not seen. Finally, a t approximately 2 hr 
postreperfusion, short, squa t villi were present, without any 
signs of subepithelial damage (Fig. 2). 
Transplantation was accompanied by a significant increase of 
the percentage of rolling leukocytes and number of adherent 
cells in the postcapillary mesenteric venules. Both primary and 
secondary leukocyte-endothelial cell interactions were signifi-
cantly reduced after ET-A receptor blockade (Fig. 3). 
I t is recognized tha t maintenance of an adequate micro-
vascular blood supply is critical for graft survival and func-
tion. There is also agreement regarding an increased rate of 
activation and accumulation of granulocytes within the isch-
emic-reperfused tissues. Previously, we reported decreased 
mesenteric blood flow and increased mesenteric vascular re-
sistance dur ing reperfusion in the same setting (4). In the 
present study, the microcircuiatory pat tern of the villus per-
fusion exhibited typical alterations during reperfusion, 
which might explain the increased macrocirculatory resis-
tance. Ordinarily, the blood reaches the villus tip in a central 
arteriole, passes the capillaries, and re turns through the 
postcapillary venules (8). Because no difference was found in 
central ar ter iolar and venular diameters and RBCV, the 
reduction in villus blood flow is not due to vasoconstriction in 
the central villus arterioles during reperfusion. The de-
creased FCD suggests tha t vasoconstriction developed at the 
level of the precapillary sphincters, i.e., a considerable pro-
portion of the inflowing blood turned back into the venules 
without passing the capillaries. 
In addition to precapillary vasoconstriction, other reperfu-
sion-related factors can also contribute to the reduction of 
FCD. The no-reflow phenomenon may develop as a result of 
interst i t ial edema formation and compression of the capillar-
ies, or it may be a resul t of intraluminal plug formation (9). 
In accordance with the lat ter , we observed increased leuko-
cyte-endothelial cell interactions in the mesenteric postcap-
illary venules. In some of the vessels, especially those with 
smal ler diameter , the adherent and rolling cells formed leu-
kocyte plugs, leading to complete obstruction of the venule. 
Although it is clear tha t the responses to ischemia-reper-
fusion involve a multiplicity of factors, our study confirms the 
ins t rumenta l role of ET-1 in these microcircuiatory reactions. 
Interestingly, we found no difference in the diameters of the 
central arterioles and postcapillary venules in response to 
ET-A antagonism. However, ET-A receptor inhibitor treat-
men t effectively a t tenuated the decrease in FCD in the in-
test inal villi, and these da ta suggest that endogenously lib-
era ted ET may be involved in the pathogenesis of capillary 
no-reflow. Depending on the localizations of the ET-A recep-
tors, a t least three possible mechanisms may be hypothe-
sized. One possibility is a differential effect of ET on the 
precapil lary sphincters, i.e., the outermost contractile ele-
ments of the circulatory system. Secondly, ET-A receptor-
mediated precapillary vasoconstriction and the ensuing hyp-
oxia could lead to perivascular edema. Indeed, it has been 
shown tha t ET-1 causes dose-dependent increases in vascu-
1514 TRANSPLANTATION Vol. 73. No. .9 
lar permeability through the activation of ET-A receptors as 
a consequence of the disruption of the endothelial barrier (6). 
Thirdly, there is evidence that ET-1 influences leukocyte 
activation in submucosal venules (3). The exact molecular 
mechanism of the pro-adhesive effect of ET-1 is still unclear. 
However, the development of firm leukocyte adhesion re-
quires the expression of adhesion molecules, and antibodies 
against P-selectin were found to reduce the ET-induced leu-
kocyte rolling in the rat (10). 
In general terms, the microenvironment is usually inacces-
sible for clinical diagnosis. The OPS imaging technique en-
abled us to visualize the villus microcirculation and detect 
the progression of the morphological-structural changes. 
During the reperfusion phase, the epithelial layer on the tip 
of the villi was gradually removed from the villus, but we did 
not observe exposed, "denuded," or "amputated" villi, which 
are characteristically seen on light microscopy. In this re-
spect, further comparative studies are needed to establish an 
in vivo scoring system similar to the histological scoring of 
intestinal biopsies. In the ET-A receptor antagonist-treated 
group, epithelial exfoliation was also present, but, it was less 
severe, and the regeneration was also faster, as indicated by 
the significantly higher epithelium. 
In conclusion, our experimental model allowed in vivo vi-
sualization of the intestinal villus microcirculation so that 
leukocyte-endothelial interactions and microvascular perfu-
sion changes could be observed simultaneously. We demon-
strated that SBTX considerably impair the microcirculation 
of the graft, as characterized by the reduced capillary perfu-
sion of the villi and the leukocyte-endothelial cell interac-
tions in the mesenteric venules. These changes led to distinc-
tive morphological injury of the villi. The differences in 
vascular responses observed after ET receptor antagonist 
treatment could define the involvement of the ET-A receptor 
subtype in the intestinal microliemodynamic alterations in 
postischemic bowel injury. 
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Endothelin-1 induces mucosal mast cell degranulation 
in the rat small intestine 
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Abstrac t 
The enhanced production of endothelial cell-derived vasoactive mediators and the activation of 
mast cells (MCs) have been implicated in the pathogenesis of mucosal damage during ischemia 
and reperfusion injuries. The first objective of our study was to define the in vivo relation between 
endothelin-1 (ET-l) and the MC system. Secondly, we determined whether pretreatment with ET re-
ceptor antagonists would attenuate MC responses to exogenous ET-l. In the first series of experi-
ments, increasing doses of ET-l (0.1, 1 and 3 nmoi/kg i.v.) were administered to anesthetized rats. 
In the second series, the animals were pretreated with equimolar doses of the ET-A reccptor antago-
nist BQ-610 or ETR-Pl / f l peptide, and the ET-B receptor antagonist IRL-1038. Intestinal perfusion 
changes and macrohcmodynamics were recorded, and the proportion of degranulated MCs was de-
termined in ileal biopsies. The average mucosal thickness was recorded with an image analysis sys-
tem. ET-1 induced dose-dependent alterations in the hemodynamic and morphological parameters 
and caused pronounced mucosal injury, with a significant reduction in villus height. The ratio of de-
granulated MCs was similar in all ET-treated groups (77%, 82% and 86%) to that observed in ani-
mals subjected to 15-min ischcmia and 60-min reperfusion (85% degranulation). Pretreatment with 
BQ-610 and ETR-Pl / f l peptide attenuated the ET-l induced alterations in the hemodynamic param-
eters and decreased structural injury to the mucosa. ET-induced MC degranulation was significantly 
inhibited by the ET-A receptor antagonists, but not by IRL-1038. These results indicate that elevated 
levels of circulating ET-l might induce intestinal mucosal tissue injury and MC degranulation via 
activation of ET-A receptors, and raise the possibility that ET-A receptor antagonist administration 
could exert a potentially beneficial effect through a mechanism other than the blockade of vasocon-
striction in pathologies associated with an increased ET-1 release. © 2000 Elsevier Science Inc. 
All rights reserved. 
Keywords: Endothelin-1: ETR-Pl/fl peptide; Endothelin-A receptor antagonist; Mast cell degranulation; Intes-
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Introduction 
The endothelins (ETs) embrace a family of 21-amino acid vasoactive peptides produced by 
the endothelial cells. Among the three active isoforms (ET-1, ET-2 and ET-3), ET-1 is the most 
powerful endogenous vasoconstrictor substance known to date [1,2]. The vasoconstrictive ef-
fects of ET-1 are mediated predominantly via the endothelin-A (ET-A) receptors present on the 
vascular smooth muscle cells. The ET-B receptors mediate vasoconstriction (ET-B2) and vasodi-
lation (ET-B,), but ET-1 has a higher affinity for ET-A than for ET-B receptor subtypes [3-5]. 
There is a growing body of evidence that, in addition to the separate role of ET-1 as a dom-
inant vasoconstrictor, the peptide may also influence the biological activity of other cell types 
in the cardiovascular system. The effect of ET-1 on the gastrointestinal mast cells (MCs) is of 
special interest, since it may be an important component of the tissue response that occurs in 
the mucosa during inflammation or reoxygenalion injuries. Intestinal MCs have both ET-A 
and ET-B receptors on their membrane surface, and this suggests a possible crosstalk be-
tween endothelial cell-derived humoral mediators and the MC system. This is supported by 
examinations revealing that ET-1 is involved in the pathogenesis of albumin-induced intesti-
nal anaphylaxis via ET-A receptor activation [6,7]. 
Recent studies have demonstrated that the production of ET-1 increases significantly dur-
ing experimental hypoxia and ischemia-reperfusion, which suggests that ET-1 may contrib-
ute to the circulatory changes in these conditions [8.9]. There is also evidence that intestinal 
ischemia-reperfusion leads to the discharge of a variety of MC-derived inflammatory com-
pounds [10]. Moreover, previous studies have indicated severe mucosal morphological alter-
ations in the small intestine in rats treated with exogenous ET-1 [11], Although these data 
support the possibility that an upregulated ET-1 release may be associated with simultaneous 
MC activation and degranulation, there is no direct experimental evidence to allow these 
findings to be ascribed to the in vivo effects of ET-1. 
The first series of our studies was directed to an examination of whether and how intestinal 
MCs respond to increasing doses of exogenousiy administered ET-1. Secondly, the hypothesis 
was evaluated that ET-1 receptor inhibition would attenuate ET-1-induced MC degranulation 
and accompanying tissue damage. To this end, the ET-1-induced microcirculatory effects were 
correlated to the indices of mucosal morphological changes and degrees of intestinal MC de-
granulation. We used ET-A receptor and ET-B receptor-selective antagonist treatments to inves-
tigate the roles of these receptor subtypes in mediating ET-l-induced intestinal MC activation. 
We present evidence that pharmacological inhibition of ET-A receptor activation reduces MC. 
degranulation and significantly decreases ET-l-induced tissue injury in the rat small intestine. 
Methods 
Animals 
The experiments described in this article were performed in adherence to the National In-
stitutes of Health guidelines on the use of experimental animals. The study was approved by 
the Animal Welfare Committee of Szent-Györgyi Albert Medical University. 
42 male Sprague-Dawley rats (weighing 200±20 g) were deprived of food but not water, 
for 12 h prior to the experiments. The animals were anesthetized with sodium pentobarbital 
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(60 mg/kg body weight i.p.) after premedication with atropine (0.1 mg/kg s.c.), and placed in 
a supine position on a heating pad for maintenance of the body temperature between 36 and 
37°C. Tracheotomy was performed and the animals were mechanically ventilated with a ro-
dent respirator (Harvard Apparatus, South Natick, MA, USA). 
Polyethylene catheters (PE 50, ID 0.58 mm. Fa. Portex, Hythe, UK) were inserted into the 
left carotid artery and jugular vein for the recording of mean arterial pressure and the injec-
tion of test compounds, respectively. Throughout the experiment, the animals received an in-
fusion of Ringer's lactate at a rate of 40 ml/kg/h. After a transverse laparotomy, a segment of 
the terminal ileum perfused by a single artery was selected. The marginal vessels were di-
vided and ligated, and the intestinal segment with intact neurovascular connections was cov-
ered by plastic sheets. 
Experimental protocol 
After surgery, the animals were allowed to stabilize for 15 min and the cardiovascular pa-
rameters were then recorded to establish the baseline variables (0 min). The animals were ran-
domly divided into groups. In the first series of experiments, dose responses to ET-1 (Alexis 
Corporation, Laufelfingen, Switzerland) were obtained. The animals were allotted into the fol-
lowing groups: group 1, sham-operated (n=6), group 2, 0.1 nmol/kg ET-1 (n=5), group 3, 1 
nmol/kg ET-1 (n=5), group 4, 3 nmol/kg ET-1 (n=6). In these groups. 30 min after the end of 
baseline measurements, a solution of 0.1 ml ET-1 or vehicle was infused i.v. into the systemic 
circulation over 15 min. An additional group of animals (n=5) served as positive control. In 
this group, segmental intestinal ischemia was induced by a 15-min occlusion of the ileal artery. 
In the second series, 3 nmol/kg ET-1 was administered in combination with ET receptor 
blockers, in these groups, the ET-A receptor antagonists ETR-Pl/fl peptide (VLNLCALS-
VDRYRAVASWRVI, Kurabo Ltd. Osaka. JapaiCOo pmol/kg). BQ-610 (0.3 (imol/kg), 
(hoffiopiperidinyi-carbonyl-Leu-D-Trp(CHO)-D-Trp-OH. Alexis Corp., Laufelfingen, Swit-
zerland), or the ET-B receptor antagonist IRL-1038 (Cysl l-Cysl5-endothelin-1(11-21), 0.3 
|xmol/kg) was infused i.v. for 30 min, followed by a 15-min of ET-1 infusion into the sys-
temic circulation after the end of BQ-610, ETR-Pl/fl peptide, or IRL-1038 pretreatment, re-
spectively [12]. The circulatory changes were observed for 60 min. At the end of the observa-
tion period, a tissue sample was taken from the intestinal segment, and the animals were then 
killed with an overdose of pentobarbital. 
Laser-Doppler measurements 
Intestinal intramural blood flow of the segment was recorded with a laser-Doppler flow 
monitor (Moor Instruments, MBF 3D, Axminster, UK). Laser-Doppler flowmetry affords an 
estimate of the tissue perfusion, based on continuous measurement of the red blood cell 
(RBC) flux (the number of red blood cells X velocity). At each observation point, 3 measure-
ments were performed over a 1 to 2-min period. 
Histology 
Intestinal biopsy samples for light microscopy were rapidly placed into ice-cold Carnoy's 
fixative and trimmed along the longitudinal axis. The fixed tissue was attached to a hard card-
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board backing to ensure the optimal longitudinal direction of the section. The samples were 
embedded in paraffin, sectioned (6 pan) and stained with hematoxylin-eosin. acidic toluidine 
blue (pH 0.5) or alcian blue-safranin O (pH 0.4). An image analysis system system (IVM, 
Pictron Kft., Budapest, Hungary) was used to digitize the x and y coordinates of the sections. 
Three nonoverlapping fields were processed in each section and the height of a single villus 
was measured from its origin to the villus tip. In each field, an average of 10 consecutive 
measurements were used to calculate the average villus height. Mucosal damage was as-
sessed according to the standard scale of Chiu et al. [13]. The grading was performed with 
the following criteria: grade 0, normal mucosa; grade 1, development of subepithelial Gruen-
hagen's space at the tip of the villus; grade 2, extension of the space with epithelial lifting; 
grade 3. massive epithelial lifting with a few denuded villi; grade 4, denuded villi with ex-
posed capillaries; and grade 5, disintegration of the lamina propria, ulceration, and hemor-
rhage. MC stained positively were quantitated in the villi of an average of 20 villus-crypi 
units. The counting was performed in coded sections at X 400 optical magnification by one 
investigator. Loss of intracellular granules, stained material dispersed diffusely within the 
lamina propria was taken as evidence of mast cell degranulation. 
Statistics 
Data analysis was performed with a statistical software package (SigmaStat for Windows. 
Jandel Scientific, Erkrath, Germany). The Friedman test followed by Dunnett's method was 
applied for multiple comparisons with a control. Differences between groups were analyzed 
with the Kruskal-Wallis one-way analysis of variance on ranks, p values <0.05 were consid-
ered significant. Mean values ± SD are given. 
Results 
The resting hemodynamic parameters were similar in each of the groups studied. In the 
first series of experiments, the increasing doses of ET-1 caused marked changes in intestinal 
hemodynamics. The intestinal RBC flux displayed a dose-dependent decrease when the MAP 
was kept elevated. The reduction in intestinal RBC flux was more pronounced in the 3 nmol/kg 
ET-1 -treated animals as compared with those undergoing 0.1 nmol/kg ET-1 treatment (Table 1). 
In the sham-operated group, the villus MC count was unchanged and no significant in-
crease in degranulation was observed in biopsies taken at the end of the observation period. A 
significant, dose-dependent diminution of the villus height was induced by ET-1 infusion as 
compared to the control group. The shortening of the villi was statistically significant after 
the administration of 1 or 3 nmol/kg ET-1, and there was a significant difference in this pa-
rameter between the 0.1 and 3 nmol/kg ET-1-treated animals (Fig. 1, upper panel). Simulta-
neously, the mucosal alterations as assessed on the Chiu scale were statistically different 
from the control in the 1 and 3 nmol/kg ET-1-treated groups (Fig. 3. upper panel). The MC 
degranulation ratio exhibited a significant increase after the ET-1 treatment. The ET-1 infu-
sions elevated the proportion of degranulated MCs almost twofold in each of the ET-1-treated 
groups (Fig. 1, lower panel). 
The ET-A receptor antagonists ETR-Pl/fl peptide and BQ-610 attenuated the ET-1-
induced fall in RBC flow. (Table 2), the reduction of villus length (Fig. 2. upper panel) and 
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Table 1 
Effect of ET-l or ischemia-reperfusion (IR) on the mean arterial pressure (MAP) and the small intestinal 
microcirulation (RBC flux) in the rat 
Treatment n MAP RBC flux 
IR ET-l doses (mm Hg) (RBC count x 
(nmol/kg i.v.) velocity) 
Baseline 6 92±16 480±44 
- - 45 min 6 91±11 487±78 c, d 
- - 105 min 6 96±20 406±57 c, d 
0.1 Baseline 5 102±7 416±73 
- 0.1 45 min 5 105±12 379±62 c, d 
- 0.1 105 min 5 107±15 345±86 a 
1 Baseline 5 95±15 513±55 
- 1 45 min 5 104±16 273±33 a, b 
- 1 105 min 5 108±26 253±44 a, b 
3 Baseline 6 93±12 540±44 
- 3 45 min 6 11Q±18 207±23 a, b 
- 3 105 min 6 88±16 235±78 a, b 
+ Baseline 4 97±5 435±62 
+ - 45 min 4 102±10 1754=40 a, b 
+ - 105 min 4 103±9 216±55 a, b 
a: p < 0.05 vs. baseline: b: p < 0.05 vs. sham-operated group: c: p < 0.05 vs. 3.0 nmol/kg ET-l-treated group: 
d: p < 0.05 vs. IR group. Values expressed as means ± SD. 
the ET-induced mucosal damage (Fig. 3, lower panel). Similarly, MC degranulation was sig-
nificantly inhibited by the ET-A receptor antagonist pretreatment (Fig. 2, lower panel). ET-B 
receptor antagonist IRL-1038 peptide administration did not influence the 3 nmol/kg ET-1-
induced local intestinal hemodynamic and morphological alterations. 
Discussion 
Impairment of splanchnic perfusion is a key event in the development of the acute circula-
tory response in systemic and local low-flow states, and the production of ET-1 increases sig-
nificantly under these conditions [14]. Previous studies have revealed severe mucosal mor-
phological alterations in the small intestine after exogenous ET-l administration [11]. There 
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Fig. J. Changes in small intestinal villus length (upper panel) and mucosal mast cell (MMC) degranuiation 
(lower panel) in rats treated with 0.1 (n=5), 1 (n=5) or 3 (n=6) nmol/kg ET-1 or following 15-min ischemia-
reperfusion (IR, n=4). In the lower panel, open bars represent the percentage of intact MMCs, while gray bars 
show the proportion of degranulated MMCs. Values are expressed as means ± SD. * p<0.05 vs. sham-operated 
group, 'p<0.0S vs. 3 nmol/kg ET-1-treated group, x p<0.()5 vs. IR group. Kruskal-Wallis one-way analysis of 
variance on ranks. 
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Table 2 
Effects of ET receptor antagonist pretreatment on the 3.0 nrnol/kg ET- i-induced changes in the mean arterial 
pressure (MAP) and the microcimclation of the rat small intestine (RBC flux) 
Treatment n MAP RBC flux 
ET receptor ET-1 (mm Hg) (RBC count x 
Antagonist (3 nmol/kg i.v.) velocity) 
Baseline 6 92±16 480444 
- - 45 min 6 91411 487478 c 
- - 105 min 6 96420 406457 c 
ETR-Pl/fl + Baseline 5 98415 435440 
ETR-Pl/fl + 45 min 5 101±14 4304117 
ETR-Pl/fl + 105 min 5 98±22 4314105 
BQ-610 + Baseline 5 103415 5054174 
BQ-610 + 45 min 5 107420 4364100 
BQ-610 + 105 min 5 95±27 5194170 c 
IRL-1038 Baseline 6 105425 513492 
IRL-1038 -p 45 min 6 123423 318450 
IRL-1038 + 105 min 6 105425 306476 a 
+ Baseline 6 93412 540444 
- + 45 min 6 110±18 207423 a, b 
- + 105 min 6 88±16 235478 a, b 
a: p < 0.05 vs. baseline; b: p < 0.05 vs. sham-operated group; e: p < 0.05 vs. 3.0 ninol/kg ET-1-treated group. 
Values expressed as means ± SD. 
is also evidence that even a short period of intestinal arterial occlusion leads to structural 
damage to the mucosal layer and triggers the discharge of a variety of MC-derived inflamma-
tory mediators into the mesenteric circulation [10,15,16], It has further been demonstrated 
that ET-1 may liberate histamine and leukotriene C4 from bone marrow-derived MCs 
through the activation of ET-A receptors [17]. 
Various data suggest a multiple connection between endothelial cell-derived vasoactive 
mediators and the activation of intestinal MCs. It has been demonstrated that inhibition of ni-
tric oxide (NO) synthesis leads to MC degranulation and a rise in microvascular permeability 
[18], It has also been found that NO may decrease the intestinal permeability secondary to 
the inhibition of MC activation [19]. The major finding of the present study is that the vaso-
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Fig. 2. Changes in small intestinal villus length (upper panel) and mucosal mast ceil (MMC) degranulation 
(lower panel) in rats treated with 3 nmol/kg ET-l (n=6) and in animals that received ET receptor antagonist pre-
treatment. ETR-PI/fl (n=5). BQ-610 (n=5) or IRL-1038 (n=6) was administered in a 300 nM/kg dose. In the 
lower panel, open bars represent the percentage of intact MMCs, while gray bars show the proportion of degranu-
lated MMCs. Values are expressed as means ± SD. *p<0.05 vs. sham-operated group, 'p<0.05 vs. 3 nmol/kg 
ET-1-treated group. Kruskal-Wallis one-way analysis of variance on ranks. 
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Fig. 3. Grading of mucosal damage according to the standard scale of Chiu. The upper panel represents the 
mucosal corruption induced by 0.1 (n=5), 1 (n=5) or 3 (n=6) nmol/kg ET-l infusion or 15-min ischemia (n=4), 
respectively. In the lower panel data on pretreatment with ETR-Pl/fl (n=5). BQ-610 (n=5) or IRL-1038 (n=6) are 
shown. Horizontal lines of boxes present the first, median and third quartiles of data. Whiskers show the 10th and 
90th percentiles. *p<0.05 vs. sham-operated group (n=6). Kruskal-Wallts one-way analysis of variance on ranks. 
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constrictor mediator ET-1 could be involved in the mechanism of induction of MC responses 
in the small intestinal mucosa. The results show that ET-1 exerts significant effects on MC 
degranulation. and concomitantly induces significant intestinal microcirculatory disturbances 
and mucosal damage via the ET-A receptors. ET-1 undergoes mainly abluminar release and 
the half-life of the peptide in the circulation is very short as a consequence of the effective 
eliminating mechanisms. However, the ET-1 plasma level usually rises 2-5-fold over the 
baseline in ischemic conditions [9,20], and other observations indicate that the intestinal en-
dothelial NO synthase activity is decreased after arterial occlusion [21], It is possible, there-
fore, that a shift in the equilibrium between endothelial cell-derived vasoconstrictor and va-
sodilator factors has a significant influence on mucosal MC responses. 
We used ET receptor antagonist pretreatmenls to separate the ET-receptor subtype-mediated 
effects of ET-1 in MC degranulation, and these changes were compared with those observed 
in the small intestine after a standardized ischemia-reperfusion challenge. The present results 
confirm that ET-1 may contribute to MC degranulation in vivo through the activation of ET-A 
receptors. 
Depending on the localizations of the ET-A receptors, at least three possible mechanisms 
may be hypothesized. One possibility might be a direct effect of ET on MCs. This notion is 
supported by the data of Liu et al. [22] demonstrating ET-A receptor expression on the sur-
face of MCs in the rat. A direct interaction between MC degranulating peptide (MDP) and 
G-proteins in MCs [23,24] has also been reported. With regard to the very close structural 
similarities between ET-1 and MDP [25], a similar connection between ET-1 and G-proteins 
in MCs might be suggested. 
On the other hand, the profound ET-A receptor-mediated microvascular vasoconstriction 
and the ensuing ischemic injury could be another plausible explanation for the MC degranu-
lation. The structural injury of the small intestinal mucosa may be directly connected with 
the hemodynamic consequences of ET administration. The mucosal lesions were similar to 
those described in animal models of intestinal ischemia-reperfusion or after nanomolar doses 
of exogenous ET-1 [11], In this case, tissue hypoxia, or oxygen-derived free radicals gener-
ated during local ischemia-reperfusion injuries could also be MC-degranulating factors. 
Another explanation may be provided by the altered osmolarity of the intestinal mucosa as 
a result of localized perivascular edema. The fragility of the MC membranes to osmotic 
stress has been demonstrated. Intraperitoneal injection of hypotonic salt solutions results in 
MC membrane destruction, without induction of the osmotic disruption of other cell types 
[26]. Indeed, Filep et al. have shown that ET-l causes dose-dependent increases in vascular 
permeability through the activation of ET-A receptors as a consequence of the disruption of 
the endothelial barrier [27], Following the decrease in arterial inflow, the declining energy 
supply for active membrane transport processes and the lack of removal of metabolites may 
be accompanied by a rapid fluid movement from the vascular lumen to the lamina propria. 
An acute circulatory breakdown may therefore rapidly cause perivascular edema, leading to 
MC degranulation. 
The ET-1-induced structural damage was characterized by a significant shortening of the 
villus height, a loss of villus epithelium, and the invasion of inflammatory cells. Similar to 
samples from the ischemic-reperfused ischemic tissue, there was a clear tendency in each 
case toward a villus height reduction. ET-A receptor antagonism by BQ-610 or ETR-Pl/fl 
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peptide was effective in reducing the morphological signs of tissue injury. In a previous 
study. ET-A receptor antagonist pretreatment significantly diminished the postocclusive dam-
age to the intestinal mucosa [28]. Our results demonstrate that ET-A receptor antagonism 
may have additional beneficial activity through the inhibition of MC reactions during intesti-
nal pathologies. 
In conclusion, exogenous ET-I infusion significantly affects the perfusion characteristics 
of the smail bowel and enhances degranulation of the intestinal MCs by an ET-A receptor-
dependent mechanism. Recent data indicate that MCs and ET-1 may both be involved in the 
mechanism of endothelial cell-leukocyte interactions and neutrophil sequestration after is-
chemia [12,29]. The MCs are located in the vicinity of the submucosal collecting venules, 
which are primary targets of leukocyte-endothelial interactions during mucosal pathologies. 
Our data suggest that an important connection exists between endothelial cell-derived hu-
moral mediators and the perivascular MC system. If ET-1 acts as an amplifier of the process 
of leukocyte activation, any alteration in this mechanism could have important consequences 
in local tissue responses. 
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Endothelin-I induces mucosal mast cell 
degranulation and tissue injury 
via ETa receptors 
M i h á l y BOROS, Lász ló SZALAY a n d József KASZAKI 
Un ive rs i t y o f Szeged, I ns t i t u t e o f Surg ica l Research, P.O. Box 4 6 4 , H - 6 7 0 1 Szeged, H u n g a r y 
A B S T R A C T 
The effects of endothelin-l (ET-I) on mucosal mast cells are of special interest, since they may be 
an important component of the tissue response that occurs during ischaemic preconditioning or 
ischaemia/re-oxygenation injuries. Increasing doses of ET-I were administered intravenously to 
anaesthetized rats. In a second series of experiments, animals were pretreated wi th the ETA 
receptor antagonists BQ-610 or ETR-PI/fl peptide, or w i th the ETB receptor antagonist IRL-
1038. Intestinal perfusion changes were recorded, and the proport ion of degranulated mast cells 
and the degree of mucosal damage were determined in ileal biopsies. ET-I induced dose-
dependent alterations in the haemodynamic and morphological parameters, and caused 
significant mast cell degranulation. These changes were inhibited significantly by pretreatment 
w i th the ETa receptor antagonists, but not w i th the ETB receptor antagonist. We conclude that 
a cross-talk exists between endothelial cell-derived humoral mediators and the intestinal mast 
cell system. 
I N T R O D U C T I O N 
The mucosal mast cells (MCs) of the gastrointestinal tract 
are a unique cellular source of bo th preformed and de 
novo synthesized mediators. They are located mainly 
around postcapillary venules, f rom where they can 
influence local tissue reactions [1], Intestinal M C s have 
both E T a and E T B receptors on their membrane surface, 
and this suggests a possible cross-talk between endo-
thelial cell-derived humoral mediators and the M C 
system [2,3]. 
O n e of the early events in low-f low condit ions is the 
p roduc t ion of activators of secondary circulatory 
responses. There is a growing b o d y of evidence that, in 
addit ion to the role of endothel in- l (ET-1) as a dominant 
vasoconstrictor [4], this pept ide may also influence the 
biological activity of other cell types in the cardiovascular 
system, including po lymorphonuclear leucocytes [5]. 
The effect of ET-1 on M C s is of special interest, since it 
may also be an important componen t of the tissue 
response that occurs in the mucosa during inflammation 
or ischaemia/reperfusion injuries. 
O u r studies were directed towards an examination of 
whether and h o w intestinal M C s respond to increasing 
doses of exogenously administered ET-1. To this end, 
ET- l - induced mucosal morphological changes were 
correlated with the degree of M C degranulation. Sec-
ondly, we used ET A - and ETB-receptor-selective 
antagonists to investigate the roles of these receptor 
subtypes in mediating ET- l - i nduced intestinal M C 
activation. 
MATERIALS A N D M E T H O D S 
Animals 
The experiments were pe r fo rmed in accordance with 
U.S. National Institutes of Heal th guidelines on the use 
Key words: ETA receptor, ETR-PI/fl peptide, mucosal damage, rat, small intestine. 
Abbreviations: ET-1, endothelin-l; MC, mast cell. 
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of experimental animals. A total of 42 male Sprague-
Dawley rats (body weight 200 + 20 g) were deprived 
of food, but not water, for 12 h prior to the experiments. 
The animals were anaesthetized with sodium pento-
barbital (60 mg/kg, intraperitoneal). The left carotid 
artery and jugular vein were cannulated for the recording 
of mean arterial pressure and the injection of test 
compounds respectively. Throughout the experiment, 
the animals received an infusion of Ringer's lactate at a 
rate of 40 ml • kg - 1 • h_ 1 . After a transverse laparotomy, 
a segment of the terminal ileum perfused by a single artery 
was selected. The marginal vessels were divided and 
ligated, and the intestinal segment with intact neur-
ovascular connections was covered by plastic sheets. 
Exper imenta l protocol 
In the first series of experiments, dose responses to ET-1 
(Alexis Corp., Laufelfingen, Switzerland) were obtained. 
The animals were randomly allotted into the following 
groups: group 1, sham-operated (n = 6); group 2, 
0.1 nmol /kg ET-1 (n = 5); group 3, 1 nmol /kg ET-1 
(n = 5); group 4, 3 nmol /kg ET-1 (n = 6). At 30 min 
after the end of baseline measurements, a solution of 
0.1 ml of ET-1 or vehicle was infused intravenously into 
the systemic circulation over 15 min. In an additional 
group of animals (n = 5) segmental intestinal ischaemia 
was induced by a 15-min occlusion of the ileal artery. 
In the second series of experiments, an ETA receptor 
antagonist {ETR-P1 / f l peptide (Kurabo Ltd, Osaka, 
Japan) or BQ-610 [homopiperidinyl-carbony!-Leu-D-
Trp (CHO)-D-Trp -OH, Alexis Corp.]}, or the ETB 
receptor antagonist IRL-1038 {[Cys11,Cys16]endothelin-
1-(11-21)}, was infused intravenously (0.3 /¿mol/kg) for 
30 min, followed by a 15-min infusion of ET-1 into the 
systemic circulation after the end of BQ-610, ETR-Pl / f l 
peptide or IRL-1038 pretreatment. The circulatory 
changes were observed for 60 min, and at the end of the 
observation period a tissue sample was taken from 
the intestinal segment. 
Histology 
Intestinal biopsy samples were placed into Carnoy's 
fixative and trimmed along the longitudinal axis. The 
samples were embedded in paraffin, sectioned (6 yzm) and 
stained with haematoxylin/eosin and Alcian Blue/ 
safranin O (pH 0.4). An image analysis system (IVM; 
Pictron Kit., Budapest, Hungary) was used to digitize the 
x and y coordinates of the sections. Three non-over-
lapping fields were processed in each section, and the 
average height of a single villus was measured f rom its 
origin to the villus tip. Mucosal damage was assessed 
according to the standard scale of Chiu et al. [5a]. The 
grading was performed with the following criteria: grade 
0, normal mucosa; grade 1, development of subepithelial 
space at the tip of the villus; grade 2, extension of 
the space with epithelial lifting; grade 3, massive epithelial 
lifting; grade 4, denuded villi; grade 5, disintegration of 
the lamina propria. Positively stained MCs were quanti-
fied in the villi of an average of 20 villus-crypt units. 
Counting was performed in coded sections at x 400 
optica] magnification by one investigator. Loss of intra-
cellular granules, with stained material dispersed 
diffusely within the lamina propria, was taken as evidence 
of M C degranulation. 
Statistics 
The Friedman test followed by Dunnett 's method was 
applied for multiple comparisons with a control. 
Differences between groups were analysed by Kruskal-
Wallis one-way A N O V A on ranks. P values of < 0.05 
were considered significant. Mean values + S.D. are given. 
RESULTS 
The resting haemodynamic parameters were similar in 
each of the groups studied (results not shown). In the 
sham-operated group, the villus M C count was un-
changed, and no significant increase in degranulation was 
observed in biopsies taken at the end of the observation 
period. A significant, dose-dependent diminution of 
villus height was induced by ET-1 infusion as compared 
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Figure I ET-1-induced MC degranulation 
Upper panel: changes in intestinal villus length in rats treated wi th 0.1, I or 
3 nmol /kg ET-1, or following 15 min of ischaemia/60 min of reperfusion (l-R). 
Significance of differences: " / > < 0 . 0 5 compared wi th sham-operated group; 
#P< 0.0S compared wi th 3 nmol /kg E M group; xP < 0.05 compared wi th 
l-R group. Lower panel: changes in mucosal MC degranulation as a percentage 
of intact MCs. Values are expressed as means + S.D. 
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Figure 2 ET-1-induced mucosal damage 
Upper panel: grading of mucosal damage after infusion of 0.1, I or 3 nmol /kg 
ET-1, or after IS min of ischaemia/SO min of reperfusion (l-R). Significance of 
differences: ' P c O . O S compared wi th sham-operated group. Lower panel: 
mucosal damage in rats that received pretreatment w i th an EI receptor antagonist. 
with the control group. The shortening of the villi was 
statistically significant after the administration of 1 or 
3 nmol /kg ET-1, and there was a significant difference in 
this parameter between the 0.1 and 3 nmol /kg ET-1 
groups (Figure 1, upper panel). The M C degranulation 
ratio exhibited a significant increase after ET-1 treatment. 
The ET-1 infusions elevated the proport ion of de-
granulated MCs almost 2-fold in each of the ET-1-
treated groups (Figure 1, lower panel). Simultaneously, 
mucosal alterations, as assessed on the Chiu scale, were 
statistically different f rom the control in the 1 and 
3 nmol /kg ET-1 groups (Figure 2). 
The E T a receptor antagonists E T R - P l / f l peptide and 
BQ-610 attenuated the ET-induced villus shortening and 
mucosal damage (Figure 3, upper panel). Similarly, M C 
degranulation was significantly inhibited by pretreatment 
with the E T a receptor antagonists (Figure 3, lower panel). 
Administration of the ET b receptor antagonist IRL-1038 
did not influence the M C degranulation and morpho-
logical alterations induced by 3 nmol /kg ET-1. 
DISCUSSION 
Previous studies have revealed that even a short period of 
intestinal arterial occlusion leads to structural damage to 
the mucosal layer and triggers the discharge of a variety 
of MC-derived inflammatory mediators into the mes-
Figure 3 Effects of pretreatment with ET receptor 
antagonists 
Upper panel: changes in small intestinal villus length in animals that pretreated 
wi th an ET receptor antagonist. ETR-Pl/f l . BQ-610 or IRL-1038 was administered 
at a dose of 300 nmol/kg. Lower panel: changes in small intestinal mucosal MC 
degranulation, as a percentage of intact MCs, in rats treated wi th 3 nmol /kg EI-1 
fol lowing ET receptor antagonist pretreatment. Significance of differences: 
" / * < 0.05 compared wi th sham-operated group; # P < 0.05 compared wi th 
3 nmol /kg ET-1 group (no ET receptor antagonist pretreatment). 
enteric circulation [1], The major finding of the present 
study is that the vasoconstrictor mediator ET-1 induces 
intestinal mucosal damage, and concomitantly exerts 
significant effects on M C degranulation via ETA 
receptors. Pretreatment with ETA receptor antagonists 
was effective in reducing the morphological signs of 
ET-1-induced structural damage. 
Depending on the localization of the ETA receptors, at 
least three possible mechanisms may be hypothesized to 
account for the observed results. (1) One possibility is a 
direct effect of ET-1 on MCs. This notion is supported 
by data demonstrating ETA receptor expression on the 
surface of MCs in the rat [2,3]. A direct interaction 
between MC-degranulating peptide and G-proteins in 
MCs has also been reported [6]. Given the very close 
structural similarities between ET-1 and M C -
degranulating peptide, a similar interaction between 
ET-1 and G-proteins in MCs might be suggested. (2) The 
profound ETA-receptor-mediated microvascular vaso-
constriction and the ensuing ischaemic injury could be 
another plausible explanation for the observed M C 
degranulation. In this case, structural injury to the small 
intestinal mucosa may be connected directly to the 
© 2002 The Biochemical Society and the Hedical Research Soriety 
H. Boros. L Szalay and J. Kaszaki 
haemodynamic consequences of ET administration. 
The mucosal lesions observed in the present study were 
similar to those described in animal models of intestinal 
ischaemia/reperfusion or after administration of nano-
molar doses of exogenous ET-1 [7]. In this case, tissue 
hypoxia, or oxygen-derived free radicals generated dur-
ing local ischaemia/reperfusion injury, could also be 
MC-degranulating factors. (3) Another explanation may 
be provided by the alteration to the osmolarity of the 
intestinal mucosa that occurs as a result of localized 
perivascular oedema. The fragility of the MC membranes 
under conditions of osmotic stress has been demon-
strated. Indeed, Filep et al. [8] have shown that ET-1 
causes dose-dependent increases in vascular permeability 
through the activation of ETA receptors as a consequence 
of the disruption of the endothelial barrier. Following the 
decrease in arterial inflow, the declining energy supply 
for active membrane transport processes and the lack of 
removal of metabolites may be accompanied by rapid 
fluid movement from the vascular lumen to the lamina 
propria. An acute circulatory breakdown may therefore 
rapidly cause perivascular oedema, leading to MC 
degranulation. 
In conclusion, infusion of exogenous ET-1 signifi-
cantly enhanced degranulation of intestinal MCs by an 
ETA-receptor-dependent mechanism. Previous data in-
dicate that MCs and ET-1 may both be involved in the 
mechanisms of endothelial-cell-leucocyte interactions 
and the sequestration of polymorphonuclear leucocytes 
after ischaemia [5,7,9]. Our results demonstrate that ETA 
receptor antagonism may have additional beneficial 
activity through the inhibition of M C reactions during 
intestinal pathologies. Similarly, these data suggest that 
an important interaction exists between endothelial cell-
derived humoral mediators and the perivascular MC 
system. If ET-1 acts as an amplifier of the process of 
leucocyte activation, any alteration in this mechanism 
could have important consequences for local tissue 
responses. 
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